Market Overview - The global Parkinson's Disease Treatment Market was valued at $5.37 billion in 2023 and is projected to reach $8.75 billion by 2032, reflecting a CAGR of 5.57% from 2024 to 2032 [1][18]. - Parkinson's disease is one of the fastest-growing neurological disorders, with a rising prevalence accelerating demand for effective therapies [5]. Treatment Landscape - Traditional medications like levodopa remain primary treatment options, with approximately 1 million individuals in the U.S. relying on it, and nearly 70% of patients receiving it at some point [5]. - Advanced interventions such as deep brain stimulation (DBS) are becoming more accessible, with over 25,000 procedures performed in the U.S. in 2023 [6]. - High therapy costs and the chronic nature of the disease are challenges, but ongoing research and expanded coverage options are improving long-term patient outcomes [7]. Market Segmentation - By Drug Class: Carbidopa-levodopa held over 30% market share in 2023, while dopamine agonists are experiencing the fastest growth rate [9]. - By Sales Channel: The retail sector accounted for 61% of the market share in 2023, with hospitals expected to have a faster CAGR during 2024-2032 [10]. Regional Insights - North America dominated the market in 2023 with a 39% share, attributed to advanced healthcare facilities and significant R&D investments [11]. - The Asia Pacific region is expected to experience the most rapid growth during the forecast period due to increased healthcare spending and awareness of neurological conditions [12]. Key Companies - Major companies in the Parkinson's treatment market include AbbVie, Johnson and Johnson, Novartis, and Teva Pharmaceutical Industries [8].

Core Insights - Royalty Pharma plc has appointed Carole Ho and Elizabeth (Bess) Weatherman to its Board of Directors, enhancing its leadership team with expertise in biopharmaceuticals and finance [1][2][3] Group 1: Board Appointments - Carole Ho is the Chief Medical Officer and Head of Development at Denali Therapeutics, with 20 years of experience in biopharma, previously serving as Vice President of Clinical Development at Genentech [2][3] - Bess Weatherman has 35 years of experience as an investor in the healthcare industry and is currently a Special Limited Partner at Warburg Pincus, having joined the firm in 1988 [3] Group 2: Company Overview - Royalty Pharma, founded in 1996, is the largest buyer of biopharmaceutical royalties and a key funder of innovation in the biopharmaceutical sector, collaborating with various innovators [4] - The company has a portfolio that includes royalties on over 35 commercial products and 16 development-stage product candidates, indicating a strong position in the market [4] Group 3: Corporate Governance - The appointment of the new board members increases independent representation on the board to over 90%, reflecting Royalty Pharma's commitment to enhanced corporate governance [5]